A new treatment without chemotherapy for indolent clinical forms of mantle cell lymphoma
A study led by researchers from the Hospital Clínic-IDIBAPS shows that a new treatment without chemotherapy is effective in treating indolent clinica1
News from The Biomedical Diagnostic Center
Developed the first genomic test for personalized HER2+ breast cancer treatments
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
It has been shown that COVID-19 can damage the placenta in pregnant women
Researchers from the CLÍNIC-IDIBAPS, the Hospital Universitari Vall d’Hebron and the Parc Taulí de Sabadell have shown the damage caused by the SARS-1
Dr. Manel Juan:" “There are no good vaccines or bad vaccines”
Interview with Dr. Manel Juan, head of the Immunology Service
AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute lymphoblastic leukaemia
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as and advanced therapy drug o1
Can you be protected against COVID-19 without antibodies?
In just a few months, the coronavirus has gone from being completely unknown to being the focus of countless scientific investigations around the wor1
Immuneel Therapeutics, Hospital Clínic de Barcelona & IDIBAPS Announce a Strategic collaboration & a License Agreement
Immuneel Therapeutics Private Limited (Immuneel) today announced that it has entered into a multi-asset collaboration and licensing agreement with Ho1
A consortium of European hospitals led by Clínic IDIBAPS is launching a cellular immunotherapy project to tackle COVID-19 with the support of Cellnex Telecom
Hospital Clínic de Barcelona-IDIBAPS and Cellnex have today signed an agreement to launch a multicentre research project that will allow better under1
A new cancer immune therapy spin-off of Hospital Clínic-IDIBAPS secures a 1.5 million-euro investment from Invivo Ventures
Hospital Clínic – IDIBAPS (Barcelona) has founded Gyala Therapeutics, a new spin-off company focused on developing new CAR-T therapies for treating h1
Liver fibrosis could be treated with gold nanoparticles
Researchers at IDIBAPS, CIBERehd and ICFO implement gold nanoparticles and plasmonics to treat liver fibrosis in mice.